MedTrace Logo

BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

NCT00414284 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2010-12-08

No results posted yet for this study

Summary

This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels. This study will also look at the pharmacokinetic data (amount of Kaletra in blood at different times).

Conditions

  • HIV Infections

Interventions

DRUG

Increased dose of Kaletra

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Community Research Initiative of New England

    lead OTHER

Principal Investigators

  • Calvin J Cohen, MD, MSc · CRI

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414284 on ClinicalTrials.gov